Rhythm Pharmaceuticals
RYTM
228 hedge funds and large institutions have $3.44B invested in Rhythm Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 87 increasing their positions, 69 reducing their positions, and 19 closing their positions.
521% more call options, than puts
Call options by funds: $21.5M | Put options by funds: $3.46M
132% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 19
26% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 69
12% more funds holding
Funds holding: 203 → 228 (+25)
3.1% less ownership
Funds ownership: 105.63% → 102.53% (-3.1%)
5% less capital invested
Capital invested by funds: $3.63B → $3.44B (-$197M)
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.4M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$74.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.5M |
| 4 |
Janus Henderson Group
London,
|
+$24.2M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$66.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$62.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$55.5M |
| 4 |
Primecap Management
Pasadena,
California
|
-$43.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$26.6M |
RYTM Hedge Fund Activity: Q1 2025 in Review
228 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2025, worth a combined $3.44B — down 5.4% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new RYTM positions and 19 closed out — a net gain of 25 holders — while 87 added to existing stakes and 69 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $87.4M. The largest seller was Frazier Life Sciences Management, cutting an estimated $66.1M.
- 228 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2025, up from 203 in Q4 2024.
- Funds reported $3.44B of Rhythm Pharmaceuticals stock for Q1 2025, down 5.4% quarter-over-quarter.
- 44 funds opened new Rhythm Pharmaceuticals positions in Q1 2025 and 19 closed out, a net change of +25 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2025 was Fidelity Investments, an estimated $87.4M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2025 was Frazier Life Sciences Management, an estimated $66.1M sold.
Based on aggregated 13F filings for Q1 2025.